Navigation Links
Drugs.com Releases Q1 Sales for Top 100 U.S. Drugs: Rough U.S Flu Season Boosts Numbers for Tamiflu
Date:5/6/2013

NEW YORK, May 6, 2013 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released first quarter 2013 U.S. prescription sales data for the top 100 drugs.

(Photo:  http://photos.prnewswire.com/prnh/20130506/PH07894-a )
(Photo:  http://photos.prnewswire.com/prnh/20130506/PH07894-b )The top five drugs have minor shifts in rank but exhibit positive growth for Q1 2013. Abilify, Otsuka's second generation antipsychotic, and Nexium, AstraZeneca's leading acid blocker, rank as the top two drugs by sales for the fourth quarter in a row. Both agents hover in the $1.5 billion range for quarterly sales.

Top Five Drugs by Sales, Q1 2013Drug Name

 

Sales ($000)

 

% Change

 (previous quarter)Abilify

$1,526,228

3.24%Nexium

$1,458,964

1.21%Cymbalta

$1,296,843

5.65%Crestor

$1,295,760

1.59%Advair Diskus

$1,277,171

6.00%Cymbalta, Eli Lilly's heavily promoted depression and pain agent, moves past Crestor, AstraZeneca's leading statin, even as Cymbalta faces end-of-year patent loss. Advair Diskus, GlaxoSmithKline's cornerstone asthma and COPD inhaler, grabs the fifth spot.

Top Five Sales Gains, Q1 2013Drug Name

 

Gain ($000)

 

% Change

(previous quarter)Tamiflu

$155,019

+65.38%Synagis

$130,943

+46.47%Advair

$72,298

+6.00%DiskusCymbalta

$69,359

+5.65%Diovan

$63,538

+13.39%The most recent U.S. influenza season hit long and hard. Roche's Tamiflu jumps 32 spots and posts a 65 percent sales increase. Other respiratory medications, including Synagis for pediatric respiratory syncytial virus and the aforementioned Advair, also saw a boost in sales gains.

"Seasonal fluctuations in pharmaceutical sales are common, particularly in cold, flu and allergy seasons," said Philip Thornton , CEO of Drugs.com. "This year's flu activity, which started about four weeks early and was relatively severe, is evident in the Tamiflu numbers."

Top Five Sales Losses, Q1 2013Drug Name

 

Loss ($000)

 

% Change

(previous quarter)modafinil

-$46,169

-17.44%Avonex

-$33,647

-9.05%Incivek

-$32,155

-12.08%enoxaparin

-$29,058

-7.37%Truvada

-$28,924

-5.11%The drugs with the top five dollar losses for the quarter each forfeit between $28 and $46 million. Avonex and Incivek make repeat appearances from last quarter.

Modafinil, the generic version of Teva's Provigil used to improve wakefulness, was launched in Q2 2012 but sales have since slowed. Sales of Biogen Idec's Avonex continue to slide in response to the approval of oral multiple sclerosis drugs, which might include their own Tecfidera. Incivek sales also dropped -- new Hepatitis C approvals are in the wings, and a serious skin reaction resulted in a newly penned Box Warning for Incivek.

Detailed data on the top 100 drugs can be accessed at:
http://www.drugs.com/stats/top100/sales

About Drugs.comDrugs.com is the leading online drug information resource with over nine million unique visitors per month (ComScore, March 2013). Providing free, independent, peer-reviewed, and up-to-date information at both consumer and professional levels, Drugs.com empowers patients and caregivers to take charge of their health and be more informed than ever before. The site includes many interactive tools and mobile apps to assist consumers, healthcare professionals and researchers, such as personal medication records, a drug interaction checker, pill identification wizard, symptom checker, pharma sales statistics and more.

For more information, visit:http://www.drugs.com/

Media Inquiries:
Drugs.com Press Officer
Email
(718) 395 2473

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Drugs.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Latest Drug Sales Data: Loss of Patent Protection Has Significant Effect, According to Drugs.com
2. Drugs.com Releases Q3 Sales for Top 100 U.S. Drugs: Singulair Drops But Nexium and Abilify Remain the Leading Brands
3. Drugs.com Releases Q4 Sales for Top 100 U.S. Drugs
4. Drugs.com Launches iOS and Android Mobile App to Empower Patients and Providers Alike
5. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
6. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
7. ShelfX Releases A Fridge That Knows What You Took
8. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
9. Stereotaxis Releases V-Sono™ Intracardiac Echocardiography Module for the Vdrive™ Remote Navigation System
10. Simbionix Releases Two New Platforms at the Upcoming DDW and AUA Events
11. Medical Alarm Begins Revenue Recognition from Largest Set of Orders -- Releases New Television Commercial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec. 2, 2016 Quantum Radiology,s Mobile Breast ... radiologist interpretation directly to women at the workplace, thereby ... such as Delta Air Lines and SunTrust Bank, and ... a component of wellness initiatives. "I think ... It enables them to have a mammogram without taking ...
(Date:12/2/2016)... , Dec. 2, 2016  Eli Lilly and Company ... guidance for 2017 and provide updated financial guidance for ... conduct a conference call on that day with the ... financial guidance. The conference call will begin ... public can access a live webcast of the conference ...
(Date:12/2/2016)... , December 2, 2016 Orthopedic ... & Support) is Expected to Gain a Significant Market Share ... Orthopedic Ailments  ... , According to a ... on Medical Implants Sterile Packaging: Clamshell Product Type Segment Projected ...
Breaking Medicine Technology:
(Date:12/2/2016)... , ... December 02, 2016 , ... ... of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic technologies, ... while maintaining fulfilling lives. “We are prolonging life 6 years in the last ...
(Date:12/2/2016)... NJ (PRWEB) , ... December 02, 2016 , ... Sourced ... Water has some unique properties including its unmatched natural purity of just 6 ppm ... clean and crisp. , Nothing Water has been available in several ShopRite and FoodTown ...
(Date:12/2/2016)... San Francisco, CA (PRWEB) , ... December 02, ... ... in digitally-enabled care journeys, announced today that it has raised $6.0 million in ... are inspired by Clarify Health’s conviction that patients and their caregivers can receive ...
(Date:12/2/2016)... ... 2016 , ... ‘Tis the season for giving! Today, 20 creative teams across ... Partnership and the Drug Enforcement Administration as part of the National Red Ribbon Week ... schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. Be ...
(Date:11/30/2016)... ... November 30, 2016 , ... Standard Process, ... an annual ranking and recognition of the largest closely held companies headquartered in ... from 2008-2016. In addition, Standard Process was awarded the Talent Award for providing ...
Breaking Medicine News(10 mins):